IBA casts off final non-core assets to hone proton therapy focus
This article was originally published in Clinica
Executive Summary
Belgian proton therapy firm Ion Beam Applications (IBA) finally looks set to complete the divestment of its non-core molecular imaging businesses to focus on proton therapy, a process it started around two years ago.